Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
TORL BioTherapeutics Raises $96M in Series C
Series CVenture Capital

TORL BioTherapeutics Raises $96M in Series C

•October 17, 2025
•Oct 17, 2025
0

Participants

Torl Biotherapeutics

Torl Biotherapeutics

company

Deal Summary

TORL BioTherapeutics LLC closed a $96 million Series C financing to advance its antibody-based immunotherapies, including the CLDN6-targeted ADC TORL-1-23. The company is a clinical-stage biotech focusing on cancer treatments and will present updated Phase 1 results at ESMO 2025.

0

Comments

Want to join the conversation?

Loading comments...